4D Molecular Therapeutics, Inc. (NASDAQ:FDMT) Receives $29.62 Consensus Target Price from Analysts

Shares of 4D Molecular Therapeutics, Inc. (NASDAQ:FDMT) have earned an average recommendation of “Moderate Buy” from the ten research firms that are covering the stock, Marketbeat Ratings reports. One investment analyst has rated the stock with a sell rating, one has issued a hold rating, seven have issued a buy rating and one has given a strong buy rating to the company. The average 12-month price target among brokerages that have issued a report on the stock in the last year is $29.6250.

FDMT has been the subject of several recent research reports. Chardan Capital upgraded 4D Molecular Therapeutics to a “strong-buy” rating in a research note on Tuesday, July 28th. B. Riley Financial reaffirmed a “buy” rating on shares of 4D Molecular Therapeutics in a report on Monday, August 17th. Wall Street Zen downgraded shares of 4D Molecular Therapeutics from a “hold” rating to a “sell” rating in a research note on Saturday, May 9th. HC Wainwright reiterated a “buy” rating and set a $36.00 price target on shares of 4D Molecular Therapeutics in a report on Monday, July 20th. Finally, The Goldman Sachs Group reissued a “buy” rating and issued a $32.00 price objective on shares of 4D Molecular Therapeutics in a research report on Thursday, August 13th.

Insiders Place Their Bets

In other 4D Molecular Therapeutics news, insider David Kirn sold 114,746 shares of 4D Molecular Therapeutics stock in a transaction dated Monday, June 22nd. The stock was sold at an average price of $10.47, for a total transaction of $1,201,390.62. Following the completion of the sale, the insider directly owned 942,485 shares of the company’s stock, valued at $9,867,817.95. The trade was a 10.85% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, insider Scott Bizily sold 9,810 shares of the company’s stock in a transaction dated Tuesday, June 23rd. The stock was sold at an average price of $12.00, for a total value of $117,720.00. Following the transaction, the insider directly owned 8,617 shares of the company’s stock, valued at approximately $103,404. This represents a 53.24% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. In the last quarter, insiders have sold 198,574 shares of company stock valued at $2,220,985. Insiders own 7.90% of the company’s stock.

Institutional Investors Weigh In On 4D Molecular Therapeutics

Several institutional investors have recently added to or reduced their stakes in the business. Jupiter Topco LLC purchased a new position in 4D Molecular Therapeutics in the second quarter valued at approximately $76,466,000. RA Capital Management L.P. lifted its position in shares of 4D Molecular Therapeutics by 23.9% during the 4th quarter. RA Capital Management L.P. now owns 5,653,211 shares of the company’s stock worth $42,399,000 after buying an additional 1,090,000 shares during the last quarter. Janus Henderson Group PLC boosted its holdings in shares of 4D Molecular Therapeutics by 13.2% in the 1st quarter. Janus Henderson Group PLC now owns 5,247,151 shares of the company’s stock valued at $48,868,000 after buying an additional 611,276 shares in the last quarter. BlackRock Inc. purchased a new position in shares of 4D Molecular Therapeutics in the 2nd quarter valued at $60,463,000. Finally, Goldman Sachs Group Inc. grew its position in shares of 4D Molecular Therapeutics by 4.2% in the 4th quarter. Goldman Sachs Group Inc. now owns 4,302,905 shares of the company’s stock valued at $32,272,000 after buying an additional 174,489 shares during the last quarter. Hedge funds and other institutional investors own 99.27% of the company’s stock.

4D Molecular Therapeutics Price Performance

4D Molecular Therapeutics stock opened at $14.67 on Monday. 4D Molecular Therapeutics has a twelve month low of $5.97 and a twelve month high of $16.93. The stock’s fifty day simple moving average is $12.21 and its 200-day simple moving average is $10.34. The company has a current ratio of 8.03, a quick ratio of 8.03 and a debt-to-equity ratio of 0.05. The firm has a market capitalization of $810.37 million, a P/E ratio of -5.58 and a beta of 2.73.

4D Molecular Therapeutics (NASDAQ:FDMT) last released its earnings results on Thursday, August 13th. The company reported ($1.04) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($1.02) by ($0.02). 4D Molecular Therapeutics had a negative net margin of 194.74% and a negative return on equity of 41.33%. The company had revenue of $3.78 million during the quarter, compared to analysts’ expectations of $3.62 million. As a group, equities analysts expect that 4D Molecular Therapeutics will post -4.09 earnings per share for the current fiscal year.

4D Molecular Therapeutics Company Profile

4D Molecular Therapeutics, founded in 2015 and headquartered in Emeryville, California, is a clinical-stage biotechnology company focused on the development of targeted gene therapies for rare diseases. The company employs its proprietary Gene Expression AAV (GEA) platform to engineer novel adeno-associated virus (AAV) capsids with enhanced tissue selectivity and transduction efficiency. This platform aims to improve the precision and durability of gene delivery compared to traditional AAV approaches.

4D’s pipeline includes both preclinical and clinical-stage programs across multiple therapeutic areas.